An overview of the most commonly used physician assessment tools is found in Table 1 . Of these, HOME and other groups have found that Eczema Area and Severity Index (EASI) and SCORing Atopic Dermatitis (SCORAD) are the only AD-specific physician outcome measures that have been validated enough to be used in both clinical trials and in a clinic setting. 1, 2 EASI assesses disease extent in 4 defined body regions (head and neck, torso, arms, and legs), evaluating severity of 4 clinical signs (erythema, induration/papulation, excoriation, and lichenification) on a 4-point scale and weights these factors based on the size of the anatomic area being evaluated. 6 Extent is measured from 0 (0% involvement) to 6 (90%-100% involvement), and severity is measured from 0 (clear) to 3 (severe) for each sign. This provides a range of EASI scores from 0 to a maximum score of 72. HOME provides practical resources to help physicians calculate EASI (available at http://www.homeforeczema.org/research/easifor-clinical-signs.aspx).
The assessment is well validated and assesses both disease extent and severity, and while it does not account for any patient-reported symptoms, there is good correlation of EASI with relevant QoL index measures. 7 It is a commonly used outcome measure in clinical trials for AD.
SCORAD is a composite score that takes into account the body surface area of involvement in AD and the severity of 6 clinical signs on a 4-point scale (erythema, edema/papulation, oozing/crusting, excoriation, lichenification, and dryness), and it incorporates a patient-reported component assessing pruritus and sleep loss. 8 Extent is measured by percent disease involvement (A), and severity is measured from 0 to 3 (B) for each sign. Subjective symptoms are scored by the patient on a visual analog scale for each of pruritus and sleep loss (C). The total score is calculated as A/5 + 7B/2 + C to a maximum score of 103. A web tool to help physicians calculate SCORAD is available at http://scorad.corti.li/.
The composite nature allows for incorporation of both physician and patient observations. It is important to note that because of the composite scoring system, SCORAD values of greater than zero may be found in clear skin due to measures of pruritus and sleeplessness, which are not disease specific. 9 Accordingly, the objective SCORAD (oSCORAD) measures extent and severity items only, to a maximum score of 83.
Overall, SCORAD has high inter-rater reliability and correlates well with both objective assessments such as EASI and Investigator Global Assessment (IGA), as well as with QoL measures such as the Dermatology Life Quality Index (DLQI). 10, 11 It is also supported by HOME as a validated assessment for clinical trial and clinical use. However, EASI may simply be more practical than SCORAD due to its broader adoption.
The Physician Global Assessment (PGA), also referred to as IGA in clinical trials, assesses overall disease severity at a given timepoint on a 5-or 6-point severity scale from clear to very severe disease. 4 Clinical characteristics of erythema, infiltration, papulation, oozing, and crusting are used as guidelines for the overall severity assessment. Most IGA scales were never validated as an outcome measure, and the Investigators' Global Atopic Dermatitis Assessment (IGADA) was the first variant of IGA that provided clear definitions to rate severity. 2, 12 In addition, multiple IGA scales exist that can make studies using this outcome difficult to interpret. Despite this, the PGA/IGA remains one of the most commonly used assessments, largely due to ease of use in the clinic and requirements by authorities for labelling. 1, 4 In fact, it is commonly used to validate other outcome measures and is considered a gold-standard clinical assessment tool.
Finally, the body surface area (BSA) measurement is a simple measure of percent body surface area involved with atopic dermatitis that does not incorporate disease severity. The lack of clear lesion borders can make this assessment challenging and variable. However, despite the lack of standardization of this tool, it is very practical and commonly used in clinic, and it has been widely used as an inclusion criterion in AD clinical trials. 13 Furthermore, this assessment sufficiently complements the PGA in providing an accurate representation of disease extent and severity, as both are relatively quick and easy to complete in a clinic setting. This is further evidenced by the psoriasis literature, in which BSA × PGA has been shown to be a practical alternative to more complicated outcome measures and correlates well with validated assessment tools. 14 Other physician assessments include the Atopic Dermatitis Severity Index (ADSI) and the Six Area, Six Sign Atopic Dermatitis (SASSAD) severity score. 6 Both assessments incorporate disease extent and severity and are sometimes used as outcome measures in clinical trials. However, these provide no additional benefit to other objective assessments used in clinical trials such as EASI and SCORAD, nor do they provide any practical benefit over PGA and BSA.
AD affects patient QoL proportionate with disease severity. 7, 15, 16 Of note, health-related QoL in AD is worse than in the general population, 17 and common patientreported symptoms in AD, including pruritus and sleep disturbance, are predictors of overall QoL. 18 In addition, health-related QoL is worse if face and anogenital areas are involved. 18 Therefore, proper assessment of patient QoL is important to understand overall disease impact and to assess treatment efficacy.
Patient-reported outcomes (PROs) are increasingly important in the development of new therapies. They assess the subjective impact of an intervention and, as such, are core outcome measures when evaluating efficacy. 19 The addition of subjective measures corroborates objective evidence of efficacy and, for AD, includes measures of patientreported itch, sleep disturbance, depression, anxiety, and overall QoL. 6, 20 An overview of the most commonly used PRO assessments is represented in Table 2 . It is important to note that no single PRO captures all elements of disease, but the addition of a PRO to an objective assessment may provide a better representation of overall disease impact. The Patient Oriented Eczema Measure (POEM) was constructed to assess symptom severity and duration in patients with AD, evaluating 7 symptoms experienced over the preceding week on a 5-point scale. 21 The 7 symptoms (itch, sleep, bleeding, weeping/oozing, cracking, flaking, and dryness/ roughness) were seen to be the most sensitive in a list of 10 identified by patients as significant disease characteristics. This assessment is validated in AD and is available in several languages, correlates well with disease severity, and is readily incorporated into dermatology clinics. It demonstrates excellent psychometric properties, including internal consistency, reliability, and sensitivity to change. 9 Importantly, this tool is being increasingly used in clinical trials and is recommended by the HOME group as the core outcome instrument for measuring patient-reported symptoms in clinical trials. 5 However, as it does not capture all clinical signs and symptoms of AD, it should be used in conjunction with an objective assessment.
Developed in the early 1990s, the Dermatology Life Quality Index (DLQI) was designed to be a robust and easily implemented assessment of skin disease-related QoL impact. 22 Each of 10 items is scored on a 4-point scale and largely assesses impact on daily activities, including work, social activities, and intimacy. The DLQI is the most commonly used QoL assessment measure in AD, is validated in several formats and languages and across many dermatologic conditions, and has good psychometric properties. 3, 22, 23 The DLQI is already in clinical use for other conditions, therefore making incorporation feasible and potentially requested by payors. 23 Notwithstanding, the DLQI was designed for use in clinical trials and not for routine practice. 22 In addition, it is not disease specific and may miss important features specific to AD.
Pruritus is a very important symptom of AD that has a significant impact on overall patient QoL. 24 Of the instruments used to quantify pruritus, the Numerical Rating Scale (NRS) is the simplest and most commonly used. 25, 26 This assessment consists of a simple rating of itch from 0 to 10, with 0 representing "no itch" and 10 representing "worst imaginable itch." This instrument is well validated and widely used in clinical trials but not validated for clinical use.
1 It correlates well with disease severity, is easy to administer, and is practical for use in a clinic setting. Similarly, the pruritus visual analog scale (VAS) measures itch on a continuum of values by asking patients to score their itch, typically by marking a hash on a horizontal line 10 cm in length. This tool has the added advantage of capturing itch across a continuum as opposed to discrete values. 25, 26 However, there are more missed data with VAS compared to NRS, especially when these are completed by patients older than 60 years. 25 In order for clinicians to use these assessments effectively, it is important to understand how each scoring result reflects disease severity. Severity strata help interpret the assessments properly; however, they are not intended for routine clinical practice and as such are not recommended for the diagnosis and assessment of AD.
27 Table 3 represents the proposed severity strata for commonly used physician assessment tools and PRO assessments. Of note, there is some minor variation between published severity strata, particularly for EASI. In addition, a recent publication of severity strata for various PROs in AD reported a low to marginal Cohen's coefficient for proposed severity strata and self-reported AD severity, suggesting modest concordance. 9, 28 Given the proliferation of clinical studies in AD and the equally prolific appearance of outcomes measures used to assess QoL, the available data suggest a need for standardization of both objective and subjective outcomes measures. 3 Overall, the available literature does not present a unified view on strata for the severity of disease. Importantly, as both objective and subjective assessments of disease severity are important to assess, consideration of clinical characteristics such as disease recurrence or persistence, as well as location of the affected areas, should be considered in the overall judgement of disease severity and consideration of therapy choice. Boguniewicz et al 29 have consensus recommendations for defining moderate-to-severe AD in clinical practice, which include ≥10% BSA or, regardless of BSA, moderate-to-severe lesions, involvement of special sites, or significant QoL impact.
In terms of practical application of these assessments, it is our expert opinion that PGA and BSA are the most practical tools for use in clinic that accurately capture the important objective elements of disease. As EASI also may be required by payors for reimbursement, health care providers should understand how to administer this assessment.
When assessing patient-reported symptoms, we recommend the use of POEM, as it captures symptoms for AD such as pruritus and sleep disturbance, which significantly affect QoL in patients with AD. DLQI or NRS may be considered, but these measures may miss some of these important features of disease. However, considering that DLQI is already in use in dermatology clinics for other conditions and that pruritus NRS is a quick and easy-to-adopt tool for use in a clinical setting, these may be considered alternatives to POEM. We recommend that if PRO instruments are not used, health care providers should ask patients about itch, sleep, and activities of daily living as these are important measures of disease severity, patient QoL, and treatment success.
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